Amylyx Pharmaceuticals (AMLX) Selling, General & Administrative (2021 - 2026)
Powered by 
Analysis
Amylyx Pharmaceuticals (AMLX) Selling, General & Administrative (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.88 Bn | 197.89 Bn | 7.24 Bn | 1.75 Bn |
| 2 | Gilead Sciences | 181.55 Bn | 178.37 Bn | 6.22 Bn | 1.92 Bn |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.45 Bn | 2.84 Bn | 582.20 Mn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | 662.10 Mn |
| 5 | Argenx Se | 61.54 Bn | 56.36 Bn | 1.37 Bn | -417.00 Mn |
| 6 | Moderna | 54.69 Bn | 49.55 Bn | 52.00 Mn | 216.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.07 Bn | 30.76 Bn | 992.69 Mn | 347.92 Mn |
| 8 | Biogen | 31.41 Bn | 30.12 Bn | 1.96 Bn | 709.70 Mn |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | 165.53 Mn |
| 10 | Amylyx Pharmaceuticals | 3.69 Bn | 3.69 Bn | - | 21.93 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 21.93 Mn |
| Mar 31, 2026 | 16.17 Mn |
| Dec 31, 2025 | 15.39 Mn |
| Sep 30, 2025 | 16.17 Mn |
| Jun 30, 2025 | 15.64 Mn |
| Mar 31, 2025 | 15.68 Mn |
| Dec 31, 2024 | 17.10 Mn |
| Sep 30, 2024 | 17.83 Mn |
| Jun 30, 2024 | 21.65 Mn |
| Mar 31, 2024 | 57.76 Mn |
| Dec 31, 2023 | 52.24 Mn |
| Sep 30, 2023 | 48.72 Mn |
| Jun 30, 2023 | 43.39 Mn |
| Mar 31, 2023 | 44.01 Mn |
| Dec 31, 2022 | 40.84 Mn |
| Sep 30, 2022 | 29.94 Mn |
| Jun 30, 2022 | 29.99 Mn |
| Mar 31, 2022 | 26.35 Mn |
| Dec 31, 2021 | 14.92 Mn |
| Sep 30, 2021 | 10.35 Mn |